Sector News

Concordia CEO heads for the exit

October 24, 2016
Life sciences

Another disciple of Valeant Pharmaceuticals and its price-hiking credo is bidding farewell to its CEO.

Concordia Pharmaceuticals said Friday that its founder and current helmsman Mark Thompson would step down as soon as the Canadian drugmaker finds a replacement.

Concordia didn’t give a reason for the switch, noting only that Thompson and the board agreed that “this would be the ideal time for a leadership change.” But he’s not the only chief exec to exit his role in what’s been a tricky year for specialty drugmakers, Concordia included.

Valeant saw J. Micheal Pearson to the door in late April, bidding goodbye to the architect of its buy-and-raise-prices strategy that’s landed the company in plenty of hot water. At the time, the company was struggling under negative short-seller commentary, price-hike pushback and formulary exclusions–all of which Concordia currently faces.

And just last month, another drugmaker that seemed to take a page from Valeant’s playbook–Endo–parted ways with its CEO. Rajiv De Silva joined Endo from Valeant, where he was president, and as the pricing debate heated up over the past year, his company has been burned badly for some of its moves.

Thompson himself has roots in Valeant’s past; he was a VP of business development at Biovail, which Valeant later acquired to move its domicile to Canada.

Like many of its peers that have come under fire for raising prices on older meds, Concordia’s price-jacking is nothing new. In June of 2014, the company raised the price on a decades-old irritable bowel syndrome product it had purchased, Donnatal, taking it to $602 from $353 per prescription. This year, Donnatal sold for $782 per prescription, an 800% increase over its 2010 price.

And more recently, price hikes ensued after Concordia bought Amdipharm Mercury from private equity firm Cinven; 16 of Amdipharm’s meds charted price increases after September 2015, the month the companies announced their deal. One clotting med’s price soared by 119% between that month and April 2016.

PBM giant CVS Health, for one, hasn’t been taking the moves lying down. It iced out a hyperinflationary med from Concordia–alongside one from Valeant–when it put together its 2017 formulary.

Concordia also ran into trouble with a short-seller earlier this year, when Marc Cohodes, a former employee of short-selling hedge fund Rocker Partners, criticized Thompson’s former employer, Biovail.

“The management of Concordia, their past gig was at something called Biovail, which I was short a long time ago [and] was a complete and utter fraud. So [Mr.] Thompson has a history of nonsense when he was at Biovail,” Cohodes said during a TV appearance on a Canadian financial news channel, words that prompted a libel lawsuit from Thompson.

All in all, the company’s stock has taken a beating as of late, sinking by nearly 80% between this July and last, which can’t be endearing Thompson to shareholders. Concordia says its search for a new chief is already underway.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach